Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Diazoxide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,961Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Soleno Therapeutics Announces FDA Review Extension for DCCR Tablets
    Soleno Therapeutics Announces FDA Review Extension for DCCR Tablets

    26 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/26/2987503/0/en/Soleno-Therapeutics-Announces-FDA-Extension-of-Review-Period-for-DCCR-Diazoxide-Choline-Extended-Release-Tablets-in-Prader-Willi-Syndrome.html

    GLOBENEWSWIRE
    26 Nov 2024
    Share Share
    Soleno Presents Diazoxide Choline in Prader-Willi Syndrome
    Soleno Presents Diazoxide Choline in Prader-Willi Syndrome

    14 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/14/2981587/0/en/Soleno-Therapeutics-Announces-Oral-Presentations-featuring-Diazoxide-Choline-Extended-Release-DCCR-Tablets-in-Prader-Willi-Syndrome-at-ESPE-2024.html

    GLOBENEWSWIRE
    14 Nov 2024
    Share Share
    Soleno Therapeutics Announces DCCR Regulatory Update
    Soleno Therapeutics Announces DCCR Regulatory Update

    08 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/10/08/2959708/0/en/Soleno-Therapeutics-Announces-Regulatory-Update-on-DCCR-diazoxide-choline-Extended-Release-Tablets-to-Treat-Prader-Willi-Syndrome.html

    GLOBENEWSWIRE
    08 Oct 2024
    Share Share
    Soleno Therapeutics To Present At Cantor Healthcare Conference
    Soleno Therapeutics To Present At Cantor Healthcare Conference

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/16/2947017/0/en/Soleno-Therapeutics-to-Present-at-2024-Cantor-Global-Healthcare-Conference.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share
    Soleno Therapeutics Announces Inducement Grants Under Nasdaq Rule
    Soleno Therapeutics Announces Inducement Grants Under Nasdaq Rule

    19 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/19/2932445/0/en/Soleno-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    19 Aug 2024
    Share Share
    Soleno Submits New Drug Application To FDA For DCCR To Treat Willi Syndrome
    Soleno Submits New Drug Application To FDA For DCCR To Treat Willi Syndrome

    28 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/28/2905801/0/en/Soleno-Therapeutics-Announces-Submission-of-New-Drug-Application-to-the-U-S-FDA-for-DCCR-Diazoxide-Choline-Extended-Release-Tablets-for-the-Treatment-of-Prader-Willi-Syndrome.html

    GLOBENEWSWIRE
    28 Jun 2024
    Share Share